Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 2

Safety and tolerability of antipsychotics: focus on amisulpride

Authors Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Published Date October 2010 Volume 2010:2 Pages 205—211

DOI http://dx.doi.org/10.2147/DHPS.S6226

Published 1 October 2010

Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira3
1Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil; 2Department of Pharmacology, Institute of Health Sciences, Federal University of Bahia, Salvador; 3Department of Neurosciences and Mental Health, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil

Abstract: The introduction of the atypical antipsychotic drugs represents an important advance in the treatment of schizophrenia, because the therapeutic efficacy, tolerability, and safety profiles of these agents seem to be superior to that of the classical neuroleptics. As would be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride is effective in acute schizophrenia as determined by Clinical Global Impression scores. The major concern regarding the safety of the atypical antipsychotics is related to their propensity to induce weight gain and alter glucose and lipid metabolism. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated with regard to anxiety and insomnia, and not notably different from placebo. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses following amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium/long-term treatment, as demonstrated in studies of up to 12 months. In terms of relevance of the effects, superiority is observed for quality of life, social adaptation, and functioning, as measured by the Quality of Life and Functional Status Questionnaire scales. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability. Moreover, this drug can help people with schizophrenia to attain social reinsertion.
Keywords: amisulpride, antipsychotic agents, safety, adverse events, tolerability
 

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Evaluation of glycophenotype in breast cancer by quantum dot-lectin histochemistry

Andrade CG, Cabral Filho PE, Tenorio DPL, Santos BS, Beltrão EIC, Fontes A, Carvalho Jr LB

International Journal of Nanomedicine 2013, 8:4623-4629

Published Date: 2 December 2013

Physiologic load-bearing characteristics of autografts, allografts, and polymer-based scaffolds in a critical sized segmental defect of long bone: an experimental study

Amorosa LF, Lee CH, Aydemir AB, Nizami S, Hsu A, Patel NR, Gardner TR, Navalgund A, Kim D-G, Park SH, Mao JJ, Lee FY

International Journal of Nanomedicine 2013, 8:1637-1643

Published Date: 24 April 2013

Nanoparticles and their potential for application in bone

Tautzenberger A, Kovtun A, Ignatius A

International Journal of Nanomedicine 2012, 7:4545-4557

Published Date: 17 August 2012

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Writing 3D patterns of microvessels

Juodkazis S

International Journal of Nanomedicine 2012, 7:3701-3702

Published Date: 13 July 2012

Reduced reward-related probability learning in schizophrenia patients

Yılmaz A, Simsek F, Gonul AS

Neuropsychiatric Disease and Treatment 2012, 8:27-34

Published Date: 5 January 2012

Outcomes of 23-gauge pars plana vitrectomy in vitreoretinal diseases

Sezgin Akçay B, Uyar OM, Akkan F, Eltutar K

Clinical Ophthalmology 2011, 5:1771-1776

Published Date: 14 December 2011

Extending the team component of the Latimer ethical decision-making model for palliative care

Purkis ME, Borycki E, Kuziemsky C, Black F, Cloutier-Fisher D, Fox LA, Mackenzie P, Syme A, Tschanz C

Journal of Healthcare Leadership 2011, 3:41-52

Published Date: 1 April 2011

Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients

Sarah Rytter Lohse, Dóra Körmendiné Farkas, Nicolai Lohse, et al

Clinical Epidemiology 2010, 2:247-250

Published Date: 27 October 2010